Thromb Haemost 1989; 62(02): 699-703
DOI: 10.1055/s-0038-1646886
Original Article
Schattauer GmbH Stuttgart

Single-Chain and Two-Chain Tissue-Type Plasminogen Activator (t-PA) Bind Differently to Cultured Human Endothelial Cells

Rob J Aerts
The Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
,
Karin Gillis
The Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
,
Hans Pannekoek
The Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 07 February 1989

Accepted after revision 06 April 1989

Publication Date:
30 June 2018 (online)

Summary

It has recently been shown that the fibrinolytic components plasminogen and tissue-type plasminogen activator (t-PA) both bind to cultured human umbilical vein endothelial cells (HUVEC). After cleavage of t-PA by plasmin, “single-chain” t-PA (sct-PA) is converted into “two-chain” t-PA (tct-PA), which differs from the former in a number of respects. We compared binding of sct-PA and tct-PA to the surface of HUVEC. Removal of t-PA bound to HUVEC by a mild treatment with acid and a subsequent quantification of eluted t-PA both by activity- and immunoradiometric assays revealed that, at concentrations between 10 and 500 nM, HUVEC bind about 3-4 times more sct-PA than tct-PA. At these concentrations, both sct-PA and tct-PA remain active when bound to HUVEC. Mutual competition experiments showed that sct-PA and tct-PA can virtually fully inhibit binding of each other to HUVEC, but that an about twofold higher concentration of tct-PA is required to prevent halfmaximal binding of sct-PA than visa versa. These results demonstrate that sct-PA and tct-PA bind with different affinities to the same binding sites on HUVEC.

 
  • References

  • 1 Bachmann F. Fibrinolysis. In: Thrombosis and Flaemostasis. Verstraete M, Vermylen J, Lijnen R, Amout J. (eds) Leuven University Press; Leuven: 1987: 227-265
  • 2 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-2919
  • 3 Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-469
  • 4 Hajjar KA, Hamel NM, Harpel PC, Nachman RL. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-1719
  • 5 Bamathan ES, Kuo A, Van der Keyl H, McCrae KR, Larsen GR, Cines DB. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. J Biol Chem 1988; 263: 7792-7799
  • 6 Beebe DP. Binding of tissue plasminogen activator to human umbilical vein endothelial cells. Thromb Res 1987; 46: 241-254
  • 7 Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-11662
  • 8 Miles LA, Levin EG, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 1988; 72: 628-635
  • 9 Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of glu-plasminogen to lys-plasminogen: further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest 1988; 82: 1769-1778
  • 10 Stern DM, Drillings M, Kisiel W, Nawroth P, Nossel HL, LaGamma K. Activation of factor IX bound to cultured bovine aortic endothelial cells. Proc Natl Acad Sci USA 1984; 81: 913-917
  • 11 Rodgers GM, Shuman M. Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci USA 1983; 80: 7001-7005
  • 12 Bevilacqua MP, Schleef RR, Grimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587-591
  • 13 Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
  • 14 Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-1600
  • 15 Gramse M, Brevario F, Pintucci G, Millet I, Dejana E, Van Damme J, Donati MB, Mussoni L. Enhancement by interleukin-1 of plasminogen activator inhibitor in cultured endothelial cells. Biochem Biophys Res Commun 1986; 139: 720-727
  • 16 Castellino FJ. Biochemistry of human plasminogen. Sem Thromb Haemostas 1984; 10: 18-23
  • 17 Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-4256
  • 18 Wallen P, Ranby M, Bergsdorf N, Kok P. Purification and characterization of tissue plasminogen activator: on the occurrence of two different forms and their enzymatic properties. Prog Chem Fibrinolysis Thrombolysis 1981; 5: 16-23
  • 19 Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338-343
  • 20 Ranby M, Wallen P. Enzymatic properties of tissue-type plasminogen activator. In: Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Collen D, Lijnen HR, Verstraete M. (eds) Churchill Livingstone; Edinburgh: 1985: 31-48
  • 21 MacDonald ME, Van Zonneveld AJ, Pannekoek H. Functional analysis of the human tissue-type plasminogen activator protein: the light chain. Gene 1986; 42: 59-67
  • 22 Sakata Y, Okada M, Noro A, Matsuda M. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells. J Biol Chem 1988; 263: 1960-1969
  • 23 Barnathan ES, Cines DB, Barone K, Kuo L, Rosenfeld L, Larsen GR. Localization of endothelial cell-binding domains of rt-PA using recombinant deletion variant rt-PAs. Circulation suppl. II 1988; 78 Abstract 1412
  • 24 Willems CN, Astaldi GC B, De Groot Ph G, Janssen MC, Gonsalvez MD, Zeijlemaker WP, Van Mourik JA, Van Aken WG. Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells. Exp Cell Res 1982; 139: 191-197
  • 25 Haigler HT, Maxfield FR, Willingham MC, Pastan I. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem 1980; 255: 1239-1241
  • 26 Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675-684
  • 27 Van Zonneveld AJ, Veerman H, Brakenhoff JD J, Aarden LA, Cajot JF, Pannekoek H. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. Thromb Haemostas 1987; 57: 82-86
  • 28 De Vries C, Veerman H, Blasi F, Pannekoek H. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins. Biochemistry 1988; 27: 2565-2572
  • 29 Majno G. Ultrastructure of the vascular membrane. In: Handbook of Physiology Section 2. Hamilton WF. (ed) American Physiological Society; Washington DC 1964: 2293
  • 30 Morrisey JH. Silver staining for proteins in polyacrylamide gels: a modified procedure with enhanced sensitivity. Anal Biochem 1981; 117: 307-310
  • 31 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685